JP2023519241A5 - - Google Patents
Info
- Publication number
- JP2023519241A5 JP2023519241A5 JP2022557755A JP2022557755A JP2023519241A5 JP 2023519241 A5 JP2023519241 A5 JP 2023519241A5 JP 2022557755 A JP2022557755 A JP 2022557755A JP 2022557755 A JP2022557755 A JP 2022557755A JP 2023519241 A5 JP2023519241 A5 JP 2023519241A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- subject
- gaba
- pam
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994805P | 2020-03-25 | 2020-03-25 | |
| US202062994803P | 2020-03-25 | 2020-03-25 | |
| US62/994,805 | 2020-03-25 | ||
| US62/994,803 | 2020-03-25 | ||
| US202063000418P | 2020-03-26 | 2020-03-26 | |
| US202063000415P | 2020-03-26 | 2020-03-26 | |
| US63/000,418 | 2020-03-26 | ||
| US63/000,415 | 2020-03-26 | ||
| US202063006671P | 2020-04-07 | 2020-04-07 | |
| US202063006672P | 2020-04-07 | 2020-04-07 | |
| US63/006,671 | 2020-04-07 | ||
| US63/006,672 | 2020-04-07 | ||
| US202063063803P | 2020-08-10 | 2020-08-10 | |
| US202063063780P | 2020-08-10 | 2020-08-10 | |
| US63/063,803 | 2020-08-10 | ||
| US63/063,780 | 2020-08-10 | ||
| PCT/US2021/024010 WO2021195297A1 (en) | 2020-03-25 | 2021-03-24 | Use of agents for treatment of respiratory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519241A JP2023519241A (ja) | 2023-05-10 |
| JP2023519241A5 true JP2023519241A5 (https=) | 2024-04-04 |
Family
ID=75478347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557755A Pending JP2023519241A (ja) | 2020-03-25 | 2021-03-24 | 呼吸器状態の処置のための薬剤の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230346801A1 (https=) |
| EP (1) | EP4125921A1 (https=) |
| JP (1) | JP2023519241A (https=) |
| KR (1) | KR20220157426A (https=) |
| CN (1) | CN115551514A (https=) |
| AU (1) | AU2021241622A1 (https=) |
| BR (1) | BR112022019085A2 (https=) |
| CA (1) | CA3176854A1 (https=) |
| CL (1) | CL2022002592A1 (https=) |
| CO (1) | CO2022013777A2 (https=) |
| IL (1) | IL296645A (https=) |
| MX (1) | MX2022011804A (https=) |
| PE (1) | PE20221911A1 (https=) |
| TW (2) | TW202202146A (https=) |
| WO (2) | WO2021195301A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| WO2022067044A1 (en) * | 2020-09-25 | 2022-03-31 | The Regents Of The University Of California | Compositions and methods for ameliorating medical conditions |
| WO2022115381A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
| US20250170147A1 (en) * | 2022-02-28 | 2025-05-29 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| EP4650359A1 (en) * | 2022-07-28 | 2025-11-19 | Hunan Kyf Pharmaceutical. Co., Ltd. | Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof |
| CN116999444B (zh) * | 2023-09-01 | 2026-03-20 | 山东中医药大学 | 四氢孕酮在制备抗流感病毒药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| HUE039057T2 (hu) | 2012-12-18 | 2018-12-28 | Univ Washington | Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok |
| EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016036724A1 (en) * | 2014-09-02 | 2016-03-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2020006599A (es) | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| WO2019226515A1 (en) * | 2018-05-21 | 2019-11-28 | The University Of North Carolina At Chapel Hill | Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders |
| CA3103421A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN112888437A (zh) * | 2018-08-22 | 2021-06-01 | 奥维德医疗公司 | 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| WO2020185710A1 (en) * | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
-
2021
- 2021-03-24 EP EP21719408.3A patent/EP4125921A1/en not_active Withdrawn
- 2021-03-24 JP JP2022557755A patent/JP2023519241A/ja active Pending
- 2021-03-24 WO PCT/US2021/024014 patent/WO2021195301A1/en not_active Ceased
- 2021-03-24 WO PCT/US2021/024010 patent/WO2021195297A1/en not_active Ceased
- 2021-03-24 MX MX2022011804A patent/MX2022011804A/es unknown
- 2021-03-24 BR BR112022019085A patent/BR112022019085A2/pt unknown
- 2021-03-24 US US17/913,936 patent/US20230346801A1/en active Pending
- 2021-03-24 AU AU2021241622A patent/AU2021241622A1/en not_active Abandoned
- 2021-03-24 US US17/913,916 patent/US20230414636A1/en active Pending
- 2021-03-24 CA CA3176854A patent/CA3176854A1/en active Pending
- 2021-03-24 KR KR1020227035963A patent/KR20220157426A/ko active Pending
- 2021-03-24 CN CN202180034342.3A patent/CN115551514A/zh active Pending
- 2021-03-24 IL IL296645A patent/IL296645A/en unknown
- 2021-03-24 PE PE2022002100A patent/PE20221911A1/es unknown
- 2021-03-25 TW TW110110914A patent/TW202202146A/zh unknown
- 2021-03-25 TW TW110110915A patent/TW202143977A/zh unknown
-
2022
- 2022-09-23 CL CL2022002592A patent/CL2022002592A1/es unknown
- 2022-09-26 CO CONC2022/0013777A patent/CO2022013777A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519241A5 (https=) | ||
| US10792289B2 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| JP2023519241A (ja) | 呼吸器状態の処置のための薬剤の使用 | |
| JP2015120751A (ja) | 薬物動態の改善のためのエアゾールフルオロキノロン配合物 | |
| US20120237564A1 (en) | Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease | |
| JP2020524172A5 (https=) | ||
| US20030073625A1 (en) | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides | |
| JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
| Pakozdi et al. | Inhaled iloprost for the treatment of Raynaud's phenomenon | |
| JP6966835B2 (ja) | 嚢胞性線維症のためのフルオロキノロン製剤 | |
| AU2015275224C1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| JP6618660B2 (ja) | 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤 | |
| HK1168786A (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| HK1168786B (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| WO2018230686A1 (ja) | 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤 | |
| AU2002248434A1 (en) | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides |